Sign in with Google. Opens in new tab
bullish
Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 2025
400 Views22 Jan 2025 10:38
SUMMARY
- Samsung Biologics (207940 KS) reported 2024 revenue of KRW4.55T, up 23% YoY, ahead of guidance of 15–20%. Growth was driven by increased contribution from Plant 4 and milestone payment.
- Ramp-Up at Plant 4 is expected to drive further revenue growth, while Plant 5, scheduled to begin operations in April 2025, will expand total production capacity to 784,000 liters.
- Samsung Biologics is well positioned to be resilient to the industry challenges. The company has guided for 20–25% YoY revenue growth to KRW5456–5684B in 2025.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Asian Dividend Gems: Septeni Holdings
- JFE Holdings (5411 JP) – Stable Core, Strategic JSW Stake, and Deep-Value Opportunity
- HEW: Playing For Time
- [Japan Event] Potentially Interesting Dynamics of Post-Tender NTT Data (9613) Trading. $8bn+ One Way
- Samsung Electronics (005930 KS) Outlook as Foundry Spin-Off Gains Momentum
Top Unpaywalled Insights
More »- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Samsung Biologics (207940 KS): 1Q25 Operating and Net Profits Doubled; 2025 Guidance Maintained24 Apr 2025
- Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 202522 Jan 2025
- Samsung Biologics (207940 KS): 3Q Result Beat Expectation; Guidance Raise Amid Increasing Order Book23 Oct 2024
- Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion25 Jul 2024
- Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares02 Jul 2024
x